Claire Ambery

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

Aili L. Lazaar, Bruce E. Miller, Alison Donald et al. · Respiratory Research · 2020 · 67 citations · Full text

Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils

Rekha Chaudhuri, Virginia Norris, Kathryn Kelly et al. · Pulmonary Pharmacology & Therapeutics · 2013 · 43 citations

Asthma, Inflammation, Anti-inflammatory +9

Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD

Eric D. Bateman, Oliver Kornmann, Claire Ambery et al. · Pulmonary Pharmacology & Therapeutics · 2013 · 36 citations

Medicine, Immunology, Pulmonary Pharmacology +3

Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement

Daphne Tsitoura, Claire Ambery, Mark Price et al. · Clinical Pharmacology & Therapeutics · 2015 · 35 citations · Full text

Asthma, Intranasal Gsk2245035, Engineering +27

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

Richard Follows, Neil G. Snowise, Shuyen Ho et al. · Respiratory Research · 2013 · 29 citations · Full text